Ethylcathinone

Ethylcathinone

Ethylcathinone

Psychoactive Research chemicals are new synthetic substances that are structurally similar to the original drug, while being functional analogs. Research on the effects of, and treatment for, abuse of these drugs is limited due to the fact that they’re fairly new and have avoided mainstream notice. Research chemicals do not have a lot of human consumption data, and thus harm-reduction and special care should be taken if choosing to ingest them.

Psychedelics are drugs which cause profound changes in a one’s perceptions of reality, otherwise known as hallucinations. While under the influence of hallucinogens, users might see images, hear sounds or feel sensations. These chemicals offer some of the most intense psychological experiences and care should be taken when ingesting them.

Disclaimer: Psychedelic drugs offer some of the most power and intense psychological experiences. Additionally these substances are illegal in many places. We understand that even though these substances are illegal, their use occurs frequently. We do not condone breaking of the law. By providing accurate information about these substances, we encourage the user to make responsible decisions and practice harm reduction.

Read the full disclaimer here.

Practice Harm Reduction. Proceed with Caution.

Description

Ethylcathinone

Also known as:

  • 1-Propanone, 2-(ethylamino)-1-phenyl-[ACD/Index Name]
  • 2-(Ethylamino)-1-phenyl-1-propanon[German][ACD/IUPAC Name]
  • 2-(Ethylamino)-1-phenyl-1-propanone[ACD/IUPAC Name]
  • 2-(Éthylamino)-1-phényl-1-propanone[French][ACD/IUPAC Name]
  • 2-(Ethylamino)-1-phenylpropan-1-one
  • HV3BCK77BB
  • UNII:HV3BCK77BB
  • 2-(ethylamine)-1-phenylpropan-1-one[ACD/IUPAC Name]
  • 2-ethylamino-1-phenylpropan-1-one
  • 2-Ethylamino-1-phenylpropanone
  • ETH-CAT
  • ETH-CAT|ethylpropion
  • Ethylaminopropionphenon
  • Ethylcathinone
  • ethylpropion
  • N-ethylaminopropiophenone
  • N-ethylcathinone

Ethylcathinone is a synthetic stimulant. It is similar to ecstasy in the sense that it provides euphoria, feelings of empathy and openness, and a desire to talk with others. It also carries over to some of the negative effects of ecstasy, such as insomnia, tightened jaw muscles, and grinding of the teeth.

Summary

It is structurally related to cathinone and methcathinone (MCAT), which broadly shares the effects profile of amphetamine or methylphenidate. Of the substituted cathinones, ETH-CAT reportedly produces the most moderate and residually long-lasting stimulation, with subtle effects that persist well after the initial rush. It has been described as having a more functional than recreational character due to the limited euphoria it produces for a stimulant, although its short active duration can promote compulsive redosing.

Very little data exists about the pharmacological properties, metabolism, and toxicity of ETH-CAT, and it has little history of human usage. It is primarily distributed as a research chemical on the online grey market. In 2008 it was identified as an ingredient in both quasi-legal “party pills”.

It has also been reported as having been sold as “ecstasy” along with another substituted cathinone, mephedrone. It is highly advised to use harm reduction practices if using this substance.

History

Chemistry

Ethylcathinone

Ethylcathinone

Substituted cathinones are all derivatives of cathinone, a stimulant substance which is structurally and functionally related to amphetamine and the principal active psychoactive component present in the khat plant (Catha edulis).

The cathinone molecule is comprised of a phenethylamine core featuring a phenyl ring bound to an amino (NH2) group at the end of an ethyl side-chain that contains ketone group in the beta position. In distinction to its N-methylated lower homolog, methcathinone (M-CAT), ETH-CAT possesses an additional ethyl substitution at Rα.

ETH-CAT can be thought of as the cathinone analog of ethylamphetamine given it has the same general formula, differing only by the addition of a single double-bonded oxygen (i.e.

the ketone group).

Common Nameethcathinone
Systematic nameethcathinone
FormulaC_{11}H_{15}NO
SMILESCCNC(C)C(=O)c1ccccc1
Std. InChiInChI=1S/C11H15NO/c1-3-12-9(2)11(13)10-7-5-4-6-8-10/h4-9,12H,3H2,1-2H3
Std. InChiKeyLYMHIBZGTAPASQ-UHFFFAOYSA-N
Avg. Mass177.2429 Da
Molecular Weight177.2429
Monoisotopic Mass177.115356 Da
Nominal Mass177
ChemSpider ID403504

Subscribe for the latest updates

Dosing Guide

Oral
Threshold30-50mg
Light50-80mg
Common80-150mg
Strong150-300mg+
Insufflated
Threshold5-20mg
Light15-30mg
Common35-70mg
Strong75-100mg+

Duration

Oral
Onset15-60 minutes
Duration2-5 hours
After-effects2-3 hours

Interactions and Synergies

Caution

  1. Mushrooms
    • Stimulants increase anxiety levels and the risk of thought loops which can lead to negative experiences
  2. LSD
    • Stimulants increase anxiety levels and the risk of thought loops which can lead to negative experiences
  3. DMT
    • Stimulants increase anxiety levels and the risk of thought loops which can lead to negative experiences
  4. Mescaline
    • The focus and anxiety caused by stimulants is magnified by psychedelics and results in an increased risk of thought loops
  5. 2C-x
    • The anxiogenic and focusing effects of stimulants increase the chance of unpleasant thought loops. The combination is generally uneccessary because of the stimulating effects of psychedelics. Combination of the stimulating effects may be uncomfortable.
  6. Cannabis
    • Stimulants increase anxiety levels and the risk of thought loops which can lead to negative experiences
  7. Ketamine
    • No unexpected interactions, though likely to increase blood pressure but not an issue with sensible doses. Moving around on high doses of this combination may be ill advised due to risk of physical injury.
  8. MXE
    • Risk of tachycardia, hypertension, and manic states
  9. Cocaine
    • This combination of stimulants will increase strain on the heart. It is not generally worth it as cocaine has a mild blocking effect on dopamine releasers like amphetamine
  10. Caffeine
    • This combination of stimulants is not generally necessary and may increase strain on the heart, as well as potentially causing anxiety and greater physical discomfort.
  11. Alcohol
    • Drinking on stimulants is risky because the sedative effects of the alcohol are reduced, and these are what the body uses to gauge drunkenness. This typically leads to excessive drinking with greatly reduced inhibitions, high risk of liver damage and increased dehydration. They will also allow you to drink past a point where you might normally pass out, increasing the risk. If you do decide to do this then you should set a limit of how much you will drink each hour and stick to it, bearing in mind that you will feel the alcohol and the stimulant less. Extended release formulations may severely impede sleep, further worsening the hangover.
  12. GHB/GBL
    • Stimulants increase respiration rate allowing a higher dose of sedatives. If the stimulant wears off first then the opiate may overcome the patient and cause respiratory arrest.
  13. Opioids
    • Stimulants increase respiration rate allowing a higher dose of opiates. If the stimulant wears off first then the opiate may overcome the patient and cause respiratory arrest.

Dangerous

  1. DOx
    • The combined stimulating effects of the two can lead to an uncomfortable body-load, while the focusing effects of amphetamine can easily lead to thought loops. Coming down from amphetamines while the DOx is still active can be quite anxiogenic.
  2. NBOMes
    • Amphetamines and NBOMes both provide considerable stimulation. When combined they can result in tachycardia, hypertension, vasoconstriction and in extreme cases heart failure. The anxiogenic and focusing effects of stimulants are also not good in combination with psychedelics as they can lead to unpleasant thought loops. NBOMes are known to cause seizures and stimulants can increase this risk.
  3. 2C-T-x
    • Stimulants increase anxiety levels and the risk of thought loops which can lead to negative experiences. In extreme cases, they can result in severe vasoconstriction, tachycardia, hypertension, and in extreme cases heart failure.
  4. 5-MeO-xxT
    • The anxiogenic and focusing effects of stimulants increase the chance of unpleasant thought loops. The combination is generally unnecessary because of the stimulating effects of psychedelics.
  5. DXM
    • Both substances raise heart rate, in extreme cases, panic attacks caused by these drugs have led to more serious heart issues.
  6. PCP
    • This combination can easily lead to hypermanic states

Low Synergy

  1. Benzodiazepines
    • Both can dull each other's effects, so if one wears off before the other it's possible to overdose due to the lack of counteraction

No Synergy

  1. SSRIs

High Synergy

  1. N2O
  2. MDMA
    • Amphetamines increase the neurotoxic effects of MDMA

General Information

Experiences
Oral
Vaporization
Come up
Dosage
Effects
After Effects
Avoid
Warning
Risks
Test Kits
Marguis Test Result
Tolerance
Detection
Half-life
Advice
Note
Note 2:
Note 3:

Effects

Pharmacological Effects

Although the effects of ETH-CAT have not been formally studied on the same level as traditional amphetamines or other substituted cathinones like methcathinone, it is possible to speculate that like other simple substituted cathinone, it most likely acts principally as a dopamine and norepinephrine reuptake inhibitor. The result of this is an effective increase in the levels of catecholamine neurotransmitters like dopamine and norepinephrine in the brain by binding to and partially blocking the transporter proteins that normally clear these neurotransmitters from the synaptic cleft. This enables dopamine and norepinephrine to accumulate between the synaptic clefts of key regions of the brain associated with reward, motivation, satisfaction and pleasure to extra-endogenous levels. This mechanism is thought to account for the stimulating, motivation enhancing and euphoric effects that this substance produces.

Subjective Effects

At low to moderate doses, ETH-CAT has been reported as being a relatively functional and effective amphetamine-like stimulant for performing general productivity tasks. It has a noticeably short duration of activity combined with a tendency to produce long-lasting residual stimulation well after the main effects have worn off, which can promote patterns of compulsive redosing in order to maintain a steady level of the desired amount of physical and cognitive stimulation.

Physical Effects

Psychological Effects

The cognitive effects of ETH-CAT can be broken down into several components which intensify proportional to dosage. The general head space of ETH-CAT is described by many as one of mental stimulation, focus enhancement and thought acceleration coupled with a mild sense of euphoria that is less pronounced than the head space of amphetamine, even at strong to heavy doses.

Visual Effects

Auditory Effects

Sensory Effects

Transpersonal Effects

Legal Status

ETH-CAT is currently a grey area compound within many parts of the world. People may still be charged for its possession under certain circumstances such as under analogue laws and with intent to sell or consume.

  • Brazil: On September 7, 2018, all cathinone analogues are controlled substances considered illegal to possess, use and distribute. This was made possible due to a blanket ban law appended to Portaria SVS/MS nº 344.
  • China: As of October 2015 Ethylcathinone is a controlled substance in China.
  • Denmark: Ethcathinone, along with mephedrone and flephedrone, was banned in Denmark on December 18, 2008.
  • Germany: Ethylcathinone is controlled under Anlage II BtMG (Narcotics Act, Schedule II) as of July 26, 2012. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
  • United Kingdom: Ethylcathinone is a Class B drug in the United Kingdom as a result of the cathinone catch-all clause.
  • United States: Ethylcathinone may be considered to be an analogue of amphetamine under the Federal Analogue Act.The Federal Analogue Act, 21 U.S.C. § 813, is a section of the United States Controlled Substances Act, allowing any chemical "substantially similar" to an illegal drug (in Schedule I or II) to be treated as if it were also in Schedule I or II, but only if it is intended for human consumption.

  • References

    1. Isomeric fluoro-methoxy-phenylalkylamines: a new series of controlled-substance analogues (designer drugs) (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/15639609
    2. Chemical analysis of four capsules containing the controlled substance analogues 4-methylmethcathinone, 2-fluoromethamphetamine, alpha-phthalimidopropiophenone and N-ethylcathinone (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/20074881
    3. Police warn of potentially fatal 'fake ecstasy' | http://www.abc.net.au/news/2008-06-17/police-warn-of-potentially-fatal-fake-ecstasy/2475270
    4. Kelly, J. P. (2011). Cathinone derivatives: a review of their chemistry, pharmacology and toxicology. Drug Testing and Analysis, 3(7‐8), 439-453. https://doi.org/10.1002/dta.31
    5. Shoptaw SJ, Kao U, Ling W. Treatment for amphetamine psychosis. Cochrane Database of Systematic Reviews, 1. https://doi.org/10.1002/14651858.CD003026.pub3
    6. Hofmann, F. G. (1983). A handbook on drug and alcohol abuse: the biomedical aspects. Oxford University Press. ISBN 9780195030570.
    7. Stimulant Misuse: Strategies to Manage a Growing Problem | http://www.acha.org/prof_dev/ADHD_docs/ADHD_PDprogram_Article2.pdf
    8. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf
    9. Gillman, P. K. (2005). Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia, 95(4), 434-441. https://doi.org/10.1093/bja/aei210
    10. Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of Medical Toxicology, 5(2), 63-67. https://doi.org/10.1007/BF03161089
    11. New blanket ban on synthetic illegal drugs is approved (Portuguese) | http://portal.anvisa.gov.br/noticias/-/asset_publisher/FXrpx9qY7FbU/content/combate-a-drogas-ilicitas-sinteticas-fica-mais-facil
    12. "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015.
    13. Forbud mod tre nye stoffer | http://nyheder.tv2.dk/article.php/id-19197033.html?forside=
    14. "Anlage II BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 25, 2019.
    15. "Sechsundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften" (in German). Bundesanzeiger Verlag. Retrieved December 25, 2019.
    16. "§ 29 BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 25, 2019.
    17. United Kingdom. (2010). Misuse of Drugs Act 1971 (S.I. 2010/1207). London: The Stationery Office Limited. Retrieved February 9, 2018, from https://www.legislation.gov.uk/uksi/2010/1207/made

    Sources

    Information made possible with:

    1. PsychonautWiki is a community-driven online encyclopedia that aims to document the field of psychonautics in a comprehensive, scientifically-grounded manner.
    2. Erowid is a non-profit educational & harm-reduction resource with 60 thousand pages of online information about psychoactive drugs
    3. PubChem National Center for Bio Informatics
    4. Chemspider is a free chemical structure database providing fast access to over 34 million structures, properties and associated information.
    5. Wikipedia

    Additional APIs were used to construct this information. Thanks for ChemSpider, NCBI, PubChem etc.

    Data is constantly updated so please check back later to see if there is any more available information on this substance.